Enzon Pharmaceuticals (OTCMKTS:ENZN) Share Price Passes Above Two Hundred Day Moving Average – Time to Sell?

Enzon Pharmaceuticals Inc. (OTCMKTS:ENZN) shares crossed above its two hundred day moving average during trading on Wednesday . The stock has a two hundred day moving average of $5.56 and traded as high as $6.0750. Enzon Pharmaceuticals shares last traded at $5.85, with a volume of 3,485 shares trading hands.

Enzon Pharmaceuticals Price Performance

The company has a market capitalization of $4.33 million, a price-to-earnings ratio of -0.86 and a beta of -0.06. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.01 and a quick ratio of 1.16. The business has a fifty day moving average price of $6.04 and a 200 day moving average price of $5.57.

Enzon Pharmaceuticals (OTCMKTS:ENZN) last issued its quarterly earnings results on Monday, May 4th. The biotechnology company reported ($0.84) EPS for the quarter. The firm had revenue of $86.54 million during the quarter.

About Enzon Pharmaceuticals

Enzon Pharmaceuticals, Inc, headquartered in Piscataway, New Jersey, is a specialized biopharmaceutical company best known for pioneering polyethylene glycol (PEG) technology to enhance the pharmacokinetic properties of therapeutic proteins. Founded in 1981, Enzon has leveraged its PEGylation platform to develop an array of oncology and hematology products with improved half-life and reduced immunogenicity.

The company’s flagship product, Oncaspar (pegaspargase), was originally approved for the treatment of acute lymphoblastic leukemia in pediatric and adult patients, highlighting Enzon’s commitment to oncology.